Summary:
In individuals with overweight or obesity, tirzepatide treatment significantly improved weight reduction (≥5%) compared to baseline and early non-responders, though it was associated with potential gastrointestinal side effects.
| PICO | Description |
|---|---|
| Population | Adults with overweight or obesity participating in the SURMOUNT-1 trial and categorized as late responders to tirzepatide. |
| Intervention | Tirzepatide administration (5 mg, 10 mg, or 15 mg doses) over an extended treatment period exceeding 12 weeks. |
| Comparison | Response was compared to weight reduction outcomes observed at 12 weeks (early response) and baseline. |
| Outcome | 90% of late responders to tirzepatide achieved ≥5% weight reduction by Week 72, surpassing early response thresholds. Tirzepatide was effective in facilitating additional weight reduction by extending treatment duration; however, mild-to-moderate gastrointestinal side effects were reported as the most frequent adverse events. |
Source: Jamy Ard, et al. “Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.” Read article here.
